← 返回

中链脂肪酸受体 GPR84 通过代谢重编程调节细胞毒性 CD8 T 细胞抗肿瘤免疫

英文原题:Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming.

查看英文原题

Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming.

PubMed 2026/04/02(内容时间) Cancer Immunol Res Q1 · IF 7.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

G蛋白偶联受体84(GPR84)是一种主要表达于髓系细胞的中链游离脂肪酸受体。既往研究已确定GPR84是促炎性髓系细胞反应的增强因子及代谢稳态的调节因子。

然而,GPR84在T细胞功能和代谢中的作用在很大程度上仍未被探索。本研究在体外测试了GPR84调控对CD8+ T细胞功能和代谢的影响,并在过继性细胞治疗模型中检验了其对 antitumor 功能的作用。使用GLPG1205进行药理学拮抗或GPR84基因缺失可促进T细胞分化、增殖、细胞因子产生和细胞毒性,而使用DL175激动则降低这些功能。这些功能变化与代谢活性的变化相平行。拮抗和基因缺失增加了葡萄糖摄取、糖酵解、氧化磷酸化和ATP产生,从而增强了整体细胞能量适应性,而激动则导致静息的能量代谢特征。

此外,在过继性细胞治疗模型中,抗原特异性CD8+ T细胞中GPR84的拮抗或缺失增强了其体内抗肿瘤效应。因此,抑制GPR84可改善CD8+ T细胞功能,并可能进一步增强过继性细胞治疗。

展开英文摘要原文

G protein-coupled receptor 84 (GPR84) is a medium-chain free fatty acid receptor predominantly expressed in myeloid cells. Previous studies have identified GPR84 as an enhancer of the pro-inflammatory myeloid cell responses and a regulator of metabolic homeostasis.

However, the role of GPR84 in T-cell function and metabolism remains largely unexplored.

This study tested the effect of GPR84 modulation on CD8+ T-cell function and metabolism in vitro and examined its effect on antitumor function in adoptive cellular therapy models. Pharmacologic antagonism with GLPG1205 or genetic deletion of GPR84 promoted T-cell differentiation, proliferation, cytokine production, and cytotoxicity, whereas agonism with DL175 reduced these functions.

These functional changes were paralleled by changes in metabolic activity. Antagonism and genetic deletion increased glucose uptake, glycolysis, oxidative phosphorylation, and ATP production, which enhanced the overall cell energetic fitness, whereas agonism resulted in a quiescent energetic profile.

Furthermore, antagonism or deletion of GPR84 in antigen-specific CD8+ T cells in adoptive cellular therapy models enhanced their antitumor effects in vivo.

Thus, GPR84 inhibition improves CD8+ T-cell function and may further enhance adoptive cellular therapies.

论文信息

作者
Philbrook P、Dean MJ、Sanchez-Pino MD、Zheng LQ、Zabaleta J、Vázquez-Martínez JA、Chang D、Mandula JK
第一作者单位
Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, Louisiana.United States
通讯作者单位
LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.United States
期刊
Cancer immunology research2026 Apr 2
原文标识
PubMed 41557755 · DOI 10.1158/2326-6066.CIR-25-0695